Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O’Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I, ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419–30.

Article  PubMed  PubMed Central  Google Scholar 

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13.

Article  PubMed Central  Google Scholar 

Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371 (9607):117–25.

Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.

Article  CAS  PubMed  Google Scholar 

Diabetes UK. How many people in the UK have diabetes? 2022. Available at: https://www.diabetes.org.uk/about-us/about-the-charity/our-strategy/statistics [Last accessed January 18, 2024].

Hex N, MacDonald R, Pocock J, et al. Estimation of the direct health and indirect societal costs of diabetes in the UK using a cost of illness model. Diabet Med. 2024;41: e15326.

Article  PubMed  Google Scholar 

Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:1–15.

Article  Google Scholar 

Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ; PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192): 39–50.

Husain M, Birkenfeld AL, Donsmark M, et al.; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381(9): 841–51.

Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4): 311–22.

National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). 2022. Available at: https://www.nice.org.uk/guidance/ng28/resources/visual-summary-full-version-choosing-medicines-for-firstline-and-further-treatment-pdf-10956472093 [Last accessed May 13, 2022].

McGuire DK, Busui RP, Deanfield J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023;25(7):1932–41.

Article  CAS  PubMed  Google Scholar 

Bain SC, Hansen BB, Malkin SJP, Nuhoho S, Valentine WJ, Chubb B, Hunt B, Capehorn M. Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme. Diabetes Ther. 2020;11(1):259–77.

Article  CAS  PubMed  Google Scholar 

Monthly Index of Medical Specialities. Diavic. 2024. Available at https://www.mims.co.uk/drugs/diabetes/oral-and-parenteral-hypoglycaemics/diavic. [Last accessed December 19, 2024].

Pollock RF, Norrbacka K, Boye KS, Osumili B, Valentine WJ. The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. J Med Econ. 2022;25(1):393–402.

Article  PubMed  Google Scholar 

van Hout M, Forte P, Jensen TB, Boschini C, Bækdal TA. Effect of various dosing schedules on the pharmacokinetics of oral semaglutide: a randomised trial in healthy subjects. Clin Pharmacokinet. 2023;62(4):635–44.

Article  PubMed  PubMed Central  Google Scholar 

American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care. 2004;27:2262–5.

Article  Google Scholar 

National Institute for Health and Care Excellence. The guidelines manual: Process and methods (PMG6). Available at: https://www.nice.org.uk/process/pmg6/resources/the-guidelines-manual-pdf-2007970804933 [Last accessed December 10, 2021].

Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925–33.

Article  CAS  PubMed  Google Scholar 

World Health Organisation. Global Health Observatory data repository: Life tables by country (United Kingdom). 2020. Available at: https://apps.who.int/gho/data/view.main.LT62260?lang=en [Last accessed December 10, 2021].

Leal J, Alva M, Gregory V, Hayes A, Mihaylova B, Gray AM, Holman RR, Clarke P. Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). Diabet Med. 2021;38(10): e14656.

Article  CAS  PubMed  Google Scholar 

Willis M, Asseburg C, Nilsson A, Johnsson K, Kartman B. Multivariate prediction equations for HbA1c lowering, weight change, and hypoglycemic events associated with insulin rescue medication in type 2 diabetes mellitus: informing economic modeling. Value Health. 2017;20(3):357–71.

Article  PubMed  Google Scholar 

Franch-Nadal J, Malkin SJP, Hunt B, Martín V, Gallego Estébanez M, Vidal J. The cost-effectiveness of oral semaglutide in Spain: a long-term health economic analysis based on the PIONEER clinical trials. Adv Ther. 2022;39(7):3180–2198.

Article  PubMed  Google Scholar 

Malkin SJP, Hunt B, Huisman EL, Grand TS, Chubb B. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials. Diabetes Res Clin Pract. 2021;175: 108759.

Article  CAS  PubMed  Google Scholar 

UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140–7.

Article  Google Scholar 

Monthly Index of Medical Specialities. Available at https://www.mims.co.uk/. [Last accessed May 10, 2023].

Rtveladze K, Hoxer CS. Cost of type 2 diabetes management and associated complications in the United Kingdom. Value Health. 2017;20(9):A477.

Article  Google Scholar 

NHS England. National Tariff Payment System 2022/23. 2022. Available at: https://www.england.nhs.uk/publication/national-tariff-payment-system-documents-annexes-and-supporting-documents/ [Last accessed May 1, 2023].

Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabetes Med. 2015;32(4):459–66.

Article  CAS  Google Scholar 

Kent S, Schlackow I, Lozano-Kuhne J, Reith C, Emberson J, Haynes R, Gray A, Cass A, Baigent C, Landray MJ, Herrington W, Mihaylova B, SHARP Collaborative Group. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? BMC Nephrol. 2015; 16: 65.

Chubb B, Tikkanen C. The cost of non-severe hypoglycaemia in Europe. Value Health. 2015;18(7):A611.

Article  Google Scholar 

Hammer M, Lammert M, Mejias SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281–90.

Article  PubMed  Google Scholar 

Jones KC, Weatherly H, Birch S, et al. Unit Costs of Health and Social Care 2022 Manual. Technical report. Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York), Kent, UK. 2023. Available at: https://www.pssru.ac.uk/unitcostsreport/ [Last accessed May 2, 2023].

Hayes A, Arima H, Woodward M, Chalmers J, Poulter N, Hamet P, Clarke P. Changes in quality of life associated with complications of diabetes: results from the ADVANCE Study. Value Health. 2016;19(1):36–41.

Article  PubMed  Google Scholar 

Briggs AH, Bhatt DL, Scirica BM, et al. Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes Res Clin Pract. 2017;130:24–33.

Article  CAS  PubMed  Google Scholar 

Shao H, Yang S, Fonseca V, Stoecker C, Shi L. Estimating quality of life decrements due to diabetes complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. Pharmacoeconomics. 2019;37(7):921–9.

Article  PubMed  PubMed Central  Google Scholar 

Bagust A, Beale S. Modelling EuroQoL health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217–30.

Article  PubMed  Google Scholar 

Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol. 2012;96(5):688–93.

Article  PubMed  Google Scholar 

Nauck MA, Buse JB, Mann JFE, et al.; LEADER Publication Committee for the LEADER Trial Investigators. Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes Obes Metab. 2019;21(3): 525–32.

Evans M, Khunti K, Mamdani M, Galbo-Jorgensen CB, Gundgaard J, Bogelund M, Harris S. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11(1):90.

Article  PubMed  PubMed Central  Google Scholar 

Abramson A, Halperin F, Kim J, Traverso G. Quantifying the value of orally delivered biologic therapies: a cost-effectiveness analysis of oral semaglutide. J Pharm Sci. 2019;108(9):3138–45.

Article  CAS  PubMed  PubMed Central